S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
This Skill Could Change The Way You Trade! (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
This Skill Could Change The Way You Trade! (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
This Skill Could Change The Way You Trade! (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
This Skill Could Change The Way You Trade! (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NYSE:BMY

Bristol-Myers Squibb - BMY Stock Forecast, Price & News

$81.13
+0.25 (+0.31%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$80.37
$81.16
50-Day Range
$68.48
$81.13
52-Week Range
$55.76
$81.43
Volume
6.37 million shs
Average Volume
9.16 million shs
Market Capitalization
$172.50 billion
P/E Ratio
26.43
Dividend Yield
2.66%
Price Target
$79.00

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
2.6% Downside
$79.00 Price Target
Short Interest
Healthy
1.15% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.30
Upright™ Environmental Score
News Sentiment
0.91mentions of Bristol-Myers Squibb in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$21.58 M Sold Last Quarter
Proj. Earnings Growth
3.82%
From $7.60 to $7.89 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

52nd out of 1,034 stocks

Pharmaceutical Preparations Industry

22nd out of 502 stocks

BMY stock logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

The Top Healthcare Stocks to Buy With $100
The Top Healthcare Stocks to Buy With $100
The 2 Best Stocks to Buy Right Now and the 2 Worst
3 Dividend Stocks to Hold Forever
1 Stock to Buy Now That Could Make You Rich in 2023
4 Stocks That Could Fetch You High Returns in 2023
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Company Calendar

Ex-Dividend for 11/1 Dividend
10/06/2022
Last Earnings
10/26/2022
Dividend Payable
11/01/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/03/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
11012210
Employees
32,200
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$94.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
-2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$6.99 billion
Pretax Margin
16.50%

Debt

Sales & Book Value

Annual Sales
$46.39 billion
Cash Flow
$12.41 per share
Book Value
$15.40 per share

Miscellaneous

Outstanding Shares
2,126,160,000
Free Float
2,124,246,000
Market Cap
$172.50 billion
Optionable
Optionable
Beta
0.40

Social Links


Key Executives

  • Dr. Giovanni Caforio M.D.Dr. Giovanni Caforio M.D. (Age 57)
    Chairman & CEO
    Comp: $5.82M
  • Mr. David V. ElkinsMr. David V. Elkins (Age 54)
    Exec. VP & CFO
    Comp: $3.18M
  • Ms. Sandra Leung Esq.Ms. Sandra Leung Esq. (Age 61)
    Exec. VP & Gen. Counsel
    Comp: $2.73M
  • Dr. Christopher S. BoernerDr. Christopher S. Boerner (Age 51)
    Exec. VP & Chief Commercialization Officer
    Comp: $2.61M
  • Mr. Rupert Vessey BCHMr. Rupert Vessey BCH (Age 57)
    BM, DPHIL, M.A., Exec. VP and Pres of Research & Early Devel.
    Comp: $3.21M
  • Mr. Greg Meyers (Age 49)
    Exec. VP and Chief Digital & Technology Officer
  • Mr. Timothy Power
    VP & Head of Investor Relations
  • Ms. Cari Gallman
    Sr. VP & Chief Compliance and Ethics Officer
  • Ms. Ann M. Powell Judge (Age 56)
    Exec. VP & Chief HR Officer
  • Mr. Jitendra Tyagi
    Head of US Drug Makers - India













BMY Stock - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2023?

13 Wall Street research analysts have issued 1 year target prices for Bristol-Myers Squibb's stock. Their BMY share price forecasts range from $60.00 to $94.00. On average, they expect the company's stock price to reach $79.00 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2022?

Bristol-Myers Squibb's stock was trading at $62.35 at the beginning of the year. Since then, BMY stock has increased by 30.1% and is now trading at $81.13.
View the best growth stocks for 2022 here
.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 24,770,000 shares, an increase of 7.3% from the October 15th total of 23,080,000 shares. Based on an average trading volume of 9,450,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.2% of the shares of the company are sold short.
View Bristol-Myers Squibb's Short Interest
.

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our BMY earnings forecast
.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) posted its earnings results on Wednesday, October, 26th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.16. The biopharmaceutical company earned $11.22 billion during the quarter, compared to analysts' expectations of $11.18 billion. Bristol-Myers Squibb had a net margin of 14.29% and a trailing twelve-month return on equity of 50.30%. The firm's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.00 EPS.
Read the conference call transcript
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Wednesday, September 14th. Investors of record on Friday, October 7th will be given a dividend of $0.54 per share on Tuesday, November 1st. This represents a $2.16 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend is Thursday, October 6th.
Read our dividend analysis for BMY
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.66%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 70.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BMY will have a dividend payout ratio of 27.38% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided earnings per share guidance of $7.44-$7.74 for the period, compared to the consensus earnings per share estimate of $7.52. The company issued revenue guidance of $46.00 billion-$46.00 billion, compared to the consensus revenue estimate of $45.97 billion.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.40%), BlackRock Inc. (8.18%), State Street Corp (4.34%), Primecap Management Co. CA (1.04%), Bank of New York Mellon Corp (0.89%) and Dimensional Fund Advisors LP (0.69%). Insiders that own company stock include Adam Dubow, Ann Powell, Autenried Paul Von, Christopher S Boerner, David V Elkins, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Rupert Vessey and Sandra Leung.
View institutional ownership trends
.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $81.13.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $172.50 billion and generates $46.39 billion in revenue each year. The biopharmaceutical company earns $6.99 billion in net income (profit) each year or $3.07 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

The company employs 32,200 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More
How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for the company is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 12/4/2022 by MarketBeat.com Staff